Food, Drugs, Healthcare, Life Sciences

The Council of the European Union has formally adopted the EU Pharma Package, marking the most significant revision of EU pharmaceutical legislation since 2004. This comprehensive reform introduces substantial changes to regulatory protection periods, innovation incentives, medicine shortage protocols, and market access mechanisms that will fundamentally reshape how pharmaceutical companies operate across the European Union.

Since July 2026, veterinary medicines manufacturers have been subject to restructured good manufacturing practice (GMP) rules under two new EU Regulations. These standalone frameworks introduce mandatory quality obligations for finished products and active substances, replacing previous guidance-based requirements with directly applicable law. Meanwhile, the European Commission's proposed Biotech Act I aims to streamline variation procedures, simplify GMO approvals, and introduce new incentives for biotechn

Q3 2026 brought significant legal and regulatory developments for the life sciences sector in Norway and the EU. This quarterly update examines key changes including enhanced transparency in Norwegian market access decisions, proposed implementation of the EU's SoHO Regulation expanding regulatory frameworks for substances of human origin, and major EU pharmaceutical reforms including the adoption of the EU Pharma Package.

The Council has adopted its position on the EU Pharmaceutical Package at first reading, with legally and linguistically revised texts now available. While the main elements of the political compromise remain intact, several clarifications warrant attention as companies refine their implementation plans and the legislative process continues toward completion.

The Council of the European Union has formally adopted the EU Pharma Package, marking the most significant revision of EU pharmaceutical legislation since 2004. This comprehensive reform introduces substantial changes to regulatory protection periods, innovation incentives, medicine shortage protocols, and market access mechanisms that will fundamentally reshape how pharmaceutical companies operate across the European Union.

Q3 2026 brought significant legal and regulatory developments for the life sciences sector in Norway and the EU. This quarterly update examines key changes including enhanced transparency in Norwegian market access decisions, proposed implementation of the EU's SoHO Regulation expanding regulatory frameworks for substances of human origin, and major EU pharmaceutical reforms including the adoption of the EU Pharma Package.

The Council of the European Union has formally adopted the EU Pharma Package, marking the most significant revision of EU pharmaceutical legislation since 2004. This comprehensive reform introduces substantial changes to regulatory protection periods, innovation incentives, medicine shortage protocols, and market access mechanisms that will fundamentally reshape how pharmaceutical companies operate across the European Union.

Operating healthcare properties presents unique challenges that distinguish them from traditional commercial real estate. From lease terms and alteration provisions to insurance arrangements...

Un nouveau décret précise les règles encadrant les communications commerciales des établissements de chirurgie esthétique en France, définissant notamment les pratiques déloyales et les communications...